



Investor News

Bayer HealthCare and CSL Behring Extend Agreement for Supply of Recombinant Factor VIII

- Global distribution deal extended through 2017
-

Leverkusen / February 1, 2007 — Bayer HealthCare announced today the extension of an agreement with CSL Behring to distribute Bayer's Recombinant Factor VIII Kogenate® under the trade name Helixate®. This agreement, effective through 2017, extends the long-standing relationship between Bayer and CSL. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia.

As part of the agreement, Bayer was granted a license to intellectual property related to the formulation of the recombinant Factor VIII product. The two companies have had a long and productive collaboration. "We strongly believe that this agreement can further develop our factor VIII franchise and that the new deal terms are attractive for both companies. It also solves all outstanding litigations," said Dr. Gunnar Riemann, Board Member Bayer HealthCare AG. "This is also a collaboration that has served the global hemophilia community through expanded distribution of our reliable Kogenate® and Helixate® line of products; reliability demonstrated by nearly two decades of clinical experience and more than 6 billion units infused," added Riemann.

"Securing the long-term supply of this life-saving therapy is significant for the patient communities we serve," said Peter Turner, president of CSL Behring. "Under this agreement, we will have the ability to increase the supply of Helixate® available for our customers. We highly value our long-term relationship with Bayer and look forward to continuing it through the next decade."

About Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany.

The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division, Bayer Schering Pharma AG, comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology.

Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Leverkusen, February 1, 2007

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ilia Kürten (+49-214-30-35426)

Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

Dr. Olaf Weber (+49-214-30-33567)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.